BlitzLab Scoring · Oct 2026 · Model v1.0 (frozen)
Insulet — Blitz Index 57 (C)
Growth re-accelerated to +30.7% with gross margin at 71.6% — a margin-proven blitz whose ceiling is set by a switching-cost moat, not a network.
57Grade C
Confidence: High · Category: frontier
Score breakdown
| Section | Score | Detail |
|---|---|---|
| A · Speed | 16 / 25 | Revenue +22.1% → +30.7% — a rare re-acceleration at device scale; international +44.1% now contributes over half the growth |
| B · Moat | 35 / 60 | Prescriber ecosystem and pharmacy-channel lock-in with high switching costs — but no network effect; B1 caps in the switching-cost band (7) |
| C · Creative destruction | 11 / 15 | The tubeless patch displaced tubed pumps and daily injections; Omnipod 5 + sensor integration rewired the daily routine |
| D · BlitzFailing | −5 | Debt stack after the 2025 convertible buyback ($949.2M incl. leases) and a first guidance cut — modest, disclosed, in the file |
Radar axes (0–100): Moat 58.3 · Speed 64 · Creative 73.3.
Watch item
Gates: G1 ✓ · G2 ✓ (estimate, borderline). Bar ≈ $27.1B (FY2025 revenue × 10) vs a ~15M-patient addressable population (company estimate) with pump penetration still low outside US Type 1.
Strengths
- FY2025 pairs +30.7% growth with gross margin +180bp to 71.6% and operating income +53% — the atlas's true signature: acceleration and margin expansion together
- International Omnipod +44.1% — the second engine is geographic
- Operating cash flow $569.3M — the blitz funds itself
- Omnipod 5 with CGM integration deepens daily-use lock-in
Concerns
- First guidance cut (Aug 2026): US Omnipod growth 20–22% → 17–19% — Type 2 expansion is slower to learn than modeled
- Patient counts and new starts are not in the SEC filings — adoption can only be inferred from revenue
- CEO/CFO transition year; Q2 2026 GAAP operating margin dipped 250bp on one-off severance
- The moat is switching costs, not network effects — the B bucket caps the total below the line
Next earnings
Nov 4, 2026 · Before open · Confirmed
Coverage
Insulet Corporation · Q3 2026 due Nov 4, 2026 (BMO, confirmed) · Score 57 · Grade C
BlitzLab scores businesses against a scholar’s standard — not investment advice. No price targets, no buy/sell recommendations. Figures are from SEC filings (XBRL) as labeled in the source scorecard.